Observational studyRheumatology (Oxford, England)2026
Body mass index and achievement of minimal disease activity in psoriatic arthritis across different classes of advanced therapy.
Observational study in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesObesity is a prevalent comorbidity in psoriatic arthritis (PsA). We aimed to evaluate the association between body mass index (BMI) and minimal disease activity (MDA) state in PsA and examine this across different drug classes.
methodsIn a longitudinal observational study using the Gladman Krembil PsA Program cohort, patients with available BMI measurement over follow-up were included. Univariable and multivariable (MV) generalized estimating equations and linear mixed models were used to assess associations between BMI and MDA (and its components) over time, adjusting for age, sex, anxiety/depression, fibromyalgia, smoking, treatment type and radiographic damage. Subgroup analyses evaluated this association across six drug classes: TNF-α inhibitors (TNFi), IL-17 inhibitors (IL-17i), IL-12/23 inhibitors (IL-12/23i), IL-23 inhibitors (IL-23i), Janus kinase inhibitors (JAKi) and phosphodiesterase-4 inhibitors (PDE4i).
resultsIn 1291 patients (mean age 44.7 years, 56% male, mean BMI 28.8 kg/m2), higher BMI was independently associated with lower odds for MDA (MV, odds ratio [OR] 0.97; 95% CI: 0.94, 0.99) along with female sex, older age, smoking, fibromyalgia and radiographic damage. BMI was negatively associated with all MDA components except swollen joint count. Higher BMI at drug initiation was associated with reduced odds for MDA state in TNFi-treated patients excluding infliximab (MV, OR 0.94; 95% CI: 0.92, 0.97), while no significant effect was seen for IL-17i, IL-12/23i, IL-23i or JAKi. Longitudinal BMI assessment similarly showed reduced MDA odds with TNFi (excluding infliximab).
conclusionsHigh BMI decreases the odds for MDA in PsA, mainly affecting subjective disease measures. This effect is most pronounced in patients treated with TNFi (except infliximab). This underscores the importance of weight management in optimizing treatment response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.